An Open-label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children From 6 to 11 Years of Age With Severe Eosinophilic Asthma

Trial Profile

An Open-label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children From 6 to 11 Years of Age With Severe Eosinophilic Asthma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 18 Jul 2016 Planned End Date changed from 1 Mar 2018 to 1 Feb 2018.
    • 11 Jul 2016 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top